On July 3, Philip Morris rose 3.06% in regular trading, trading at $183.3/share, with turnover of $4.67 billion. The rally was driven by the US FDA issuing Modified Risk Tobacco Product (MRTP) orders for 20 ZYN nicotine pouch variants.

The authorization allows Philip Morris to market the explicit claim that using ZYN instead of cigarettes puts consumers at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. This marks the first time a nicotine pouch product has received such a regulatory designation, carrying significant commercial implications for ZYN — the company's fastest-growing consumer brand. ZYN was first authorized for sale in the US in January of the prior year.

Additionally, Philip Morris recently made an early $1.1 billion prepayment toward the 5-year segment of its senior unsecured term loan, with approximately $1.7 billion remaining under that facility with a June expiration. The move optimizes the company's debt structure and enhances financial flexibility for future strategic investments or shareholder returns.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)